BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.

A 28-year-old woman with recently diagnosed chronic myelogenous leukemia (CML) presents for consideration of appropriate treatment. No siblings are available as candidate donors for stem-cell transplantation. Imatinib, an inhibitor of the BCR-ABL tyrosine kinase present in almost all CML, is recommended. The patient may need to take imatinib indefinitely to maintain suppression of abnormal bone marrow clones.

[1]  J. Bajpai.  Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial , 2008 .

[2]  R. Larson,et al.  A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) , 2007 .

[3]  J. Radich,et al.  Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. , 2007, Blood.

[4]  R. Larson,et al.  Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. , 2007, Blood.

[5]  M. Baccarani,et al.  Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. , 2007, Blood.

[6]  H. Kantarjian,et al.  Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.

[7]  J. Cayuela,et al.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. , 2005, Blood.

[8]  P. Loehrer.  Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate , 2007 .

[9]  P. Pilot,et al.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[10]  H. Kantarjian,et al.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[11]  M. Baccarani,et al.  Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia , 2006, Clinical Cancer Research.

[12]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[13]  H. Kantarjian,et al.  Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. , 2006, Blood.

[14]  D. Horsman,et al.  Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. , 2006, Cancer genetics and cytogenetics.

[15]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[16]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[17]  J. Wagner,et al.  Adult umbilical cord blood transplantation: a comprehensive review , 2006, Bone Marrow Transplantation.

[18]  J. Cortes,et al.  Chronic myeloid leukemia: diagnosis and treatment. , 2006, Mayo Clinic proceedings.

[19]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[20]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[21]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[22]  M. Copland,et al.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. , 2006, Blood.

[23]  H. Kantarjian,et al.  Pregnancy among patients with chronic myeloid leukemia treated with imatinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Brand,et al.  Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 2006, Haematologica.

[25]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[26]  Peter Lloyd,et al.  Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.

[27]  C. Sawyers,et al.  Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. , 2004 .

[28]  G. Flandrin,et al.  Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia , 2004, Leukemia.

[29]  J. Radich,et al.  Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. , 2004, Hematology/oncology clinics of North America.

[30]  Jorge Cortes,et al.  Natural history and staging of chronic myelogenous leukemia. , 2004, Hematology/oncology clinics of North America.

[31]  John P Klein,et al.  Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants , 2004, British journal of haematology.

[32]  H. Kantarjian,et al.  High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. , 2004, Blood.

[33]  J. Melo,et al.  Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[34]  L. Mariani,et al.  Gynaecomastia in men with chronic myeloid leukaemia after imatinib , 2003, The Lancet.

[35]  J. Ford,et al.  Practical management of patients with chronic myeloid leukemia receiving imatinib. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[37]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[38]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[39]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[40]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[41]  R. Bataille,et al.  Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  C Chastang,et al.  Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. , 1997, The New England journal of medicine.

[43]  Sante Tura,et al.  Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.

[44]  C. Bloomfield,et al.  Prolonged subcutaneous administration of recombinant α2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and leukemia group B study 8583 , 1993 .

[45]  O. Witte,et al.  Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[46]  C. Bloomfield,et al.  Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. , 1993, Blood.

[47]  G. Daley,et al.  Blast crisis in a murine model of chronic myelogenous leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[48]  H. Kantarjian,et al.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. , 1986, The New England journal of medicine.

[49]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[50]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .